Pediatric diffuse large B-cell lymphoma(DLBCL)is a highly aggressive disease with unique clinical characteristics.This study analyzed the germinal-center type B-cell(GCB)classification and clinical characteristics of ...Pediatric diffuse large B-cell lymphoma(DLBCL)is a highly aggressive disease with unique clinical characteristics.This study analyzed the germinal-center type B-cell(GCB)classification and clinical characteristics of Chinese pediatric DLBCL.A total of 76 patients with DLBCL newly diagnosed in Sun Yatsen University Cancer Center between February 2000 and May 2011,with an age younger than 18 years,were included in the analysis.The male/female ratio was 3.47:1.The median age was 12 years(range,2 to 18 years),and 47(61.8%)patients were at least 10 years old.Of the 76 patients,48(63.2%)had stage III/IV disease,9(11.8%)had bone marrow involvement,1(1.3%)had central nervous system(CNS)involvement,and 5(6.6%)had bone involvement.The GCB classification was assessed in 45 patients:26(57.8%)were classified as GCB subtype,and 19(42.2%)were classified as non-GCB subtype.The modified B-NHL-BFM-90/95 regimen was administered to 50 patients,and the 4-year event-free survival(EFS)rate was 85.8%.Among these 50 patients,31 were assessed for the GCB classification:17(54.8%)were classified as GCB subtype,with a 4-year EFS rate of 88.2%;14(45.2%)were classified as non-GCB subtype,with a 4-year EFS rate of 92.9%.Our data indicate that bone marrow involvement and stage III/IV disease are common in Chinese pediatric DLBCL patients,whereas the percentage of patients with the GCB subtype is similar to that of patients with the non-GCB subtype.The modified B-NHL-BFM-90/95protocol is an active and effective treatment protocol for Chinese pediatric patients with DLBCL.展开更多
目的探讨泛素特异性蛋白酶10(ubiquitin-specifi c protease 10,USP10)蛋白及其m RNA在人弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)与淋巴结反应性增生(reactive lymph node hyperplasia,RLH)中的表达及其临床意义。方...目的探讨泛素特异性蛋白酶10(ubiquitin-specifi c protease 10,USP10)蛋白及其m RNA在人弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)与淋巴结反应性增生(reactive lymph node hyperplasia,RLH)中的表达及其临床意义。方法选取70例人DLBCL及70例RLH组织,采用组织芯片和免疫组织化学染色检测USP10的蛋白表达,分析其与DLBCL分子亚型及DLBCL预后相关分子之间的关系,并采用GEO数据库分析USP10 m RNA表达水平。结果 USP10在DLBCL组织中的阳性表达率显著高于RLH组织的B淋巴细胞,在非生发中心亚型(non-germinal center B-cell-like type,nonGCB)DLBCL组织中的阳性表达率明显高于生发中心亚型(germinal center B-cell-like type,GCB)DLBCL组织;Spearman等级相关分析显示,USP10与DLBCL预后相关分子中的CD5、Bcl-2蛋白表达呈正相关,而与p53,c-Myc及Ki67蛋白表达无相关性;USP10 m RNA在DLBCL组织及RLH组织中的表达差异。结论 USP10在DLBCL组织中的表达明显增加,尤其是在预后较差的non-GCB亚型或CD5阳性或无Bcl-2阳性的DLBCL中,表明该蛋白是DLBCL患者预后不良的分子标记物之一。展开更多
文摘Pediatric diffuse large B-cell lymphoma(DLBCL)is a highly aggressive disease with unique clinical characteristics.This study analyzed the germinal-center type B-cell(GCB)classification and clinical characteristics of Chinese pediatric DLBCL.A total of 76 patients with DLBCL newly diagnosed in Sun Yatsen University Cancer Center between February 2000 and May 2011,with an age younger than 18 years,were included in the analysis.The male/female ratio was 3.47:1.The median age was 12 years(range,2 to 18 years),and 47(61.8%)patients were at least 10 years old.Of the 76 patients,48(63.2%)had stage III/IV disease,9(11.8%)had bone marrow involvement,1(1.3%)had central nervous system(CNS)involvement,and 5(6.6%)had bone involvement.The GCB classification was assessed in 45 patients:26(57.8%)were classified as GCB subtype,and 19(42.2%)were classified as non-GCB subtype.The modified B-NHL-BFM-90/95 regimen was administered to 50 patients,and the 4-year event-free survival(EFS)rate was 85.8%.Among these 50 patients,31 were assessed for the GCB classification:17(54.8%)were classified as GCB subtype,with a 4-year EFS rate of 88.2%;14(45.2%)were classified as non-GCB subtype,with a 4-year EFS rate of 92.9%.Our data indicate that bone marrow involvement and stage III/IV disease are common in Chinese pediatric DLBCL patients,whereas the percentage of patients with the GCB subtype is similar to that of patients with the non-GCB subtype.The modified B-NHL-BFM-90/95protocol is an active and effective treatment protocol for Chinese pediatric patients with DLBCL.
文摘目的探讨泛素特异性蛋白酶10(ubiquitin-specifi c protease 10,USP10)蛋白及其m RNA在人弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)与淋巴结反应性增生(reactive lymph node hyperplasia,RLH)中的表达及其临床意义。方法选取70例人DLBCL及70例RLH组织,采用组织芯片和免疫组织化学染色检测USP10的蛋白表达,分析其与DLBCL分子亚型及DLBCL预后相关分子之间的关系,并采用GEO数据库分析USP10 m RNA表达水平。结果 USP10在DLBCL组织中的阳性表达率显著高于RLH组织的B淋巴细胞,在非生发中心亚型(non-germinal center B-cell-like type,nonGCB)DLBCL组织中的阳性表达率明显高于生发中心亚型(germinal center B-cell-like type,GCB)DLBCL组织;Spearman等级相关分析显示,USP10与DLBCL预后相关分子中的CD5、Bcl-2蛋白表达呈正相关,而与p53,c-Myc及Ki67蛋白表达无相关性;USP10 m RNA在DLBCL组织及RLH组织中的表达差异。结论 USP10在DLBCL组织中的表达明显增加,尤其是在预后较差的non-GCB亚型或CD5阳性或无Bcl-2阳性的DLBCL中,表明该蛋白是DLBCL患者预后不良的分子标记物之一。
